A global pivotal (Phase 2/3) study of povetacicept in Primary Membranous Nephropathy in Greater China.
Latest Information Update: 15 May 2025
At a glance
- Drugs Povetacicept (Primary)
- Indications IgA nephropathy; Membranous glomerulonephritis
- Focus Registrational; Therapeutic Use
Most Recent Events
- 15 May 2025 New trial record
- 08 May 2025 According to Zai labs media release, company plans to partner with Vertex to execute the global pivotal (Phase 2/3) study of povetacicept in Primary Membranous Nephropathy in Greater China in 2025.